09:58 AM EDT, 08/12/2026 (MT Newswires) -- Summit Therapeutics ( SMMT ) partner Akeso has received marketing authorization from China's National Medical Products Administration for ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer, Summit said Wednesday.

The approval, based on a late-stage trial, marks the third NMPA-approved indication in China for an ivonescimab-containing regimen, Summit said.

The trial showed statistically significant and clinically meaningful improvements in both progression-free

and overall survival versus tislelizumab plus chemotherapy, the biopharmaceutical oncology company said.

Shares of Summit Therapeutics ( SMMT ) were up more than 2% in recent Wednesday trading.

Price: 15.54, Change: +0.42, Percent Change: +2.78